Discontinued — last reported Q1 '26
EBITDA at other companies
Other financials
Where this comes from
Calculated from Pacific Biosciences of California’s reported figures.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's EBITDA?
- Pacific Biosciences of California (PACB) reported EBITDA of -$5.14M in Q1 2026.
- How has Pacific Biosciences of California's EBITDA changed year-over-year?
- Pacific Biosciences of California's EBITDA increased by 91.1% year-over-year, from -$57.41M to -$5.14M.
- What is the long-term trend for Pacific Biosciences of California's EBITDA?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's EBITDA has grown at a -4.1% compound annual growth rate (CAGR), from -$202.84M to -$171.43M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.